MLN0128
Total Payments
$1.9M
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $41,843 | 1 | 0 |
| 2018 | $1.8M | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase II study of TAK228 in patients with previously treated metastatic Renal Cell Carcinoma | Takeda Pharmaceuticals U.S.A., Inc. | $655,536 | 0 |
| Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer.ANETT Trial. | Takeda Pharmaceuticals U.S.A., Inc. | $467,551 | 0 |
| MLN0128 in recurrent/metastatic merkel cell carcinoma | Takeda Pharmaceuticals U.S.A., Inc. | $414,538 | 0 |
| An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002 | Takeda Pharmaceuticals U.S.A., Inc. | $192,556 | 0 |
| Phase 1b neoadjuvant run-in study with TAK-228 followed by Letrozole/TAK-228 in women with high-risk ER+/HER2- breast cancer. | Takeda Pharmaceuticals U.S.A., Inc. | $70,693 | 0 |
| A Phase I study of TAK-228 (MLN0128) in combination with Carboplatin plus Paclitaxel in patients with advanced malignancies | Takeda Pharmaceuticals U.S.A., Inc. | $41,843 | 0 |
| An Open Label Phase I Study of Brentuximab Vedotin Plus TAk228 for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+ Peripheral T-Cell Lymphomas | Takeda Pharmaceuticals U.S.A., Inc. | $26,947 | 0 |
Top Doctors Receiving Payments for MLN0128
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Indianapolis, IN | $1.9M | 7 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.9M
- Total Doctors 0
- Transactions 7
About MLN0128
MLN0128 is a drug associated with $1.9M in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2018 to 2019. In 2019, $41,843 was paid across 1 transactions to 0 doctors.
The most common payment nature for MLN0128 is "Unspecified" ($1.9M, 100.0% of total).
MLN0128 is associated with 7 research studies, including "A Phase II study of TAK228 in patients with previously treated metastatic Renal Cell Carcinoma" ($655,536).